Phase II Study of ZD1839 (Iressa), Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor in Patients With Advanced, Recurrent or Metastatic Salivary Gland Cancer (IRUSIRES0198).

Trial Profile

Phase II Study of ZD1839 (Iressa), Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor in Patients With Advanced, Recurrent or Metastatic Salivary Gland Cancer (IRUSIRES0198).

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Sep 2016

At a glance

  • Drugs Gefitinib (Primary)
  • Indications Salivary gland cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Sep 2016 Status changed from active, no longer recruiting to completed.
    • 18 May 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Nov 2017, as reported by ClinicalTrials.gov.
    • 18 May 2015 Planned primary completion date changed from 1 Nov 2015 to 1 Nov 2016 as reported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top